Last reviewed · How we verify

NCT07316712

Effect of TECAR (Transfer of Energy Capacitive and Resistive) Therapy on Chronic Supraspinatus Tendinitis

Not yet recruiting NA Last updated 5 January 2026
What this trial tests

NA trial testing Conventional treatment in Supraspinatus Tendinitis in 46 participants. Not yet recruiting.

Timeline
30 December 2025
Primary endpoint
15 February 2026
28 February 2026

Quick facts

Lead sponsorCairo University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment46
Start date30 December 2025
Primary completion15 February 2026
Estimated completion28 February 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 30 to 55, any sex, with Supraspinatus Tendinitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the effect of TECAR therapy on pain, shoulder range of motion, functional disability, and handgrip strength in patients with grade II supraspinatus tendinitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Conventional treatment

Trials testing the same drug.

Other recruiting trials for Supraspinatus Tendinitis

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07316712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing